First FDA approval without trials
Enlarge image

Clinical TrialsUK

First FDA approval without trials

18.12.2012 - GSK’s monoclonal antibody against anthrax is the first to get FDA approval without having been tested for efficacy in humans.

This antibody is a very special one: fast track designation, priority review, orphan drug designation – and the first monoclonal antibody approved under the FDA’s Animal Efficacy Rule: On 14 December, the U.S. Food and Drug Administration (FDA) approved GlaxoSmithKline’s (GSK) raxibacumab injections as a treatment against inhalational anthrax. „In addition to antibiotics, raxibacumab will be a useful treatment to have available should an anthrax bioterrorism event occur,“ said the FDA official Edward Cox. The decision comes as no surprise, as GSK announced that the FDA’s Anti-Infective Drugs Advisory Committee voted 16 to 1 in support of the clinical benefit of raxibacumab – with one abstention on 2 November. The antibody was discovered in a joint venture between Cambridge Antibody Technology and Human Genome Sciences with Cambridge Antibody Technology discovering the antibody to Human Genome Sciences' target. In July 2012 HGS was purchased by GSK.

Inhalational anthrax is a form of the infectious disease caused by breathing in the spores of the bacterium Bacillus anthracis. Raxibacumab neutralizes toxins produced by the bacterium that can cause massive and irreversible tissue injury and death. Raxibacumab has additionally been approved to prevent inhalational anthrax when alternative therapies are not available or not appropriate. Its efficacy has been shown so far in rabbits and monkeys. „Sixty-four percent of animals in the monkey study and 44 percent of animals in one rabbit study receiving the 40 milligrams per kilogram dose of raxibacumab survived exposure to anthrax, compared with none in the placebo groups,“ said GSK in a press release. Trials in humans are not possible due the nature of the disease: Inhalational anthrax is as rare as it is lethal. However, at least the safety of raxibacumab could be demonstrated in 326 healthy human volunteers.



26.11.2015 Bioeconomy movers and shakers from every corner of the globe met this week at the world’s first Global Bioeconomy Summit in Berlin to discuss, debate and define better ways to ensure the bioeconomy succeeds on an international level.


24.11.2015 After weeks of speculation it is official: US pharma major Pfizer and Irish Botox maker Allergan will merge. With the deal, Pfizer is planning to dodge the high US taxes, causing indignation among US politicians.


23.11.2015 Amidst talk of the IPO window closing and cancelled flotations, diagnostics firms are still striking a chord with investors. Swedish Immunovia and German Curetis are successfully raising public money.


20.11.2015 French Sanofi and British AstraZeneca are giving open innovation a go: The two pharma giants will exchange thousands of compounds – for free.


19.11.2015 French gene editing company Cellectis has granted Servier the rights to bring cancer immunotherapy UCART19 to market. Servier in turn has teamed up with Pfizer to hurry development along.


17.11.2015 The first Italian accelerator specifically for biotech projects has been launched with help from Sofinnova Partners. The plan of BiovelocITA: to help Italy grow into one of Europe’s strongest biotech markets.


13.11.2015 Scientists in Bath, UK, have developed a medical dressing that turns fluorescent green when it detects infection. The researchers hope that the smart burns dressing will help fight antibiotic resistance.


13.11.2015 Out with the old: Roche is discarding four sites with 1,200 staff in an effort to restructure its manufacturing network for small molecules. Instead, a new manufacturing site will be built in Switzerland.


10.11.2015 Algae have many skills, but cancer fighting was not one of them – until now. Researchers from Australia and Germany have genetically engineered diatom algae to accurately deliver chemotherapeutic drugs.


10.11.2015 AstraZeneca has plucked Californian biopharma company ZS Pharma from under Actelion’s nose. The UK company is paying US$2.7bn (€2.5bn) to acquire ZS and its promising hyperkalaemia treatment currently under US regulatory review.


All Events


Strasbourg (F)

BioFIT 2015

Current issue

All issues

Product of the week


Stock list

All quotes


  • EPIGENOMICS (D)2.26 EUR20.86%
  • SAREUM HOLDINGS (UK)0.21 GBP10.53%


  • THERAMETRICS (CH)0.04 CHF-20.00%
  • CO.DON (D)2.35 EUR-7.84%
  • DIAMYD MEDICAL -B- (S)9.40 SEK-6.00%


  • PLETHORA (UK)5.50 GBP76.3%
  • PROTHENA PLC (IE)73.19 USD40.9%


  • EPIGENOMICS (D)2.26 EUR-49.9%
  • EVOCUTIS (UK)0.09 GBP-40.0%


  • KARO BIO (S)37.80 SEK5300.0%
  • CHRONTECH PHARMA (S)0.34 SEK1600.0%
  • GALAPAGOS (B)46.32 EUR259.1%


  • BIOTEST (D)15.77 EUR-80.4%
  • EVOCUTIS (UK)0.09 GBP-78.6%

No liability assumed, Date: 26.11.2015